Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Approves AbbVie’s Drug For Rare Leukemia

XTALKS VITALS NEWS

FDA

The drug is the first FDA-approved treatment that targets a key protein – known as B-cell lymphoma 2 (BCL-2) protein – involved in cancer cell growth.

Share this!

April 13, 2016 | by Sarah Massey, M.Sc.

The US Food and Drug Administration (FDA) has approved AbbVie’s Venclexta as a second-line treatment for chronic lymphocytic leukemia, in patients with a chromosomal abnormality known as a 17p deletion. The drug is the first FDA-approved treatment that targets a key protein – known as B-cell lymphoma 2 (BCL-2) protein – involved in cancer cell growth.

Chronic lymphocytic leukemia is among the most common types of leukemia in adults, according to the National Cancer Institute. The disease is characterized by the accumulation of abnormal lymphocytes, and 15,000 new cases of the cancer are diagnosed each year.

Patients with chronic lymphocytic leukemia who also have a deletion on the short arm of the 17th chromosome – known as a 17p mutation – lack the genes necessary to suppress the growth of cancer cells. Around 10 percent of patients with untreated forms of chronic lymphocytic leukemia have this mutation, while closer to 20 percent of patients with relapsed leukemia have the chromosomal abnormality.

“These patients now have a new, targeted therapy that inhibits a protein involved in keeping tumor cells alive,” said Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “For certain patients with chronic lymphocytic leukemia who have not had favorable outcomes with other therapies, Venclexta may provide a new option for their specific condition.”



Venclexta was tested in a single-arm clinical trial of leukemia patients with the 17p mutation, who had previously been treated with at least one other therapy. Patients were given an increasing daily dose of the drug, starting with 20mg and reaching a peak dose of 400mg at five weeks of treatment.

The results of the trial showed that 80 percent of patients experienced full or partial remission of their cancer after receiving Venclexta. “BCL-2 inhibition is a novel mechanism which brings a new treatment option to patients who need additional therapies,” said AbbVie CEO, Richard Gonzalez.

Venclexta received a number of advantageous designations from the FDA, including priority review status, accelerated approval, breakthrough therapy and orphan drug status. AbbVie and Roche’s Genentech will both be responsible for marketing the drug in the US.


Keywords: FDA, Leukemia, Rare Disease


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

READ THESE NEXT
Nanoparticles Could Be Used To Treat Inflammatory Bowel Disease

April 12, 2016 - Researchers at the Institute for Biomedical Sciences at Georgia State University in the US, and Southwest University in China, have designed a novel nanoparticle capable of blocking expression of a glycoprotein that promotes intestinal inflammation.


AstraZeneca and Eli Lilly Pursue Late-Stage Clinical Trial For Alzheimer’s Drug

April 11, 2016 - Pharmaceutical powerhouses AstraZeneca and Eli Lilly have announced that they will be pushing their experimental Alzheimer’s candidate into a Phase III clinical trial.


FDA Approves Celltrion’s Remicade Biosimilar

April 11, 2016 - Celltrion’s Inflectra – a biosimilar to Janssen Biotech’s Remicade – is the second biosimilar to be approved by the US Food and Drug Administration (FDA).

 
THE XTALKS VITALS LIFE SCIENCE BLOG

The Surprising Link Between Off-Label Prescribing Practices And Adverse Drug Events

REGISTER FOR THESE WEBINARS

Copyright © 2016-2017 Honeycomb Worldwide Inc.